Klinik für Innere Medizin 3, Schwerpunkt Pneumologie

Universitätsklinik der Paracelsus Medizinischen Privatuniversität

Portrait_Brückl 2 Prof. Dr. med. Wolfgang Brückl, Oberarzt

Leitung Pneumologische Onkologie

Tel: 0911/398-2674
E-Mail: wolfgang.brueckl@klinikum-nuernberg.de
Fax: 0911/398-2441

Prof.-Ernst-Nathan-Str. 1
90419 Nürnberg
Deutschland
Haus: 14, 4

Qualifikationen

                       

Schwerpunkte:

[nach oben]

 

Publikationen

Publikationen zum Thema Lungentumore (relevant, in Pub Med gelistet)

Brueckl WM, Reck M, Rittmeyer A, Kollmeier J, Wesseler C, Wiest GH, et al. Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. Clin Med Insights Oncol. 2020;14:1179554920951358.

 

Brueckl WM, Ficker JH, Zeitler G. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). BMC Cancer. 2020;20(1):1185.

 

Brueckl WM, Achenbach HJ, Ficker JH, Schuette W. Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study. BMC Cancer. 2018;18(1):333.

 

Bruckl WM, Ficker JH, Tiemann M, Schumann C, Reinmuth N, Heigener D, et al. [Rebiopsy for Patients with Lung Cancer - Joint Opinion from both the Endoscopic and Thoracic Oncology Sections of the German Society of Pneumology (DGP)]. Pneumologie. 2018;72(9):617-23.

 

Erber R, Stohr R, Herlein S, Giedl C, Rieker RJ, Fuchs F, Brueckl WM. Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer(R) Assay with PD-L1 Protein Expression Assessed

with Immunohistochemistry in Non-small Cell Lung Cancer. Anticancer Res. 2017;37(12):6771-8.

 

Brueckl WM. Treatment choice in EGFR-mutant non-small-cell lung cancer. Lancet Oncol. 2017;18(11):1425-6.

 

Bruckl WM, Wirtz RM, Bertsch T, Ficker JH, Jung A. Liquid Biopsy: Detection of Molecular Markers for Treatment Decisions in Lung Cancer. Pneumologie. 2017;71(3):151-63.

 

Bruckl WM, Tufman A, Huber RM. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs. Expert Rev Anticancer Ther. 2017;17(2):143-55.

 

Doesch J, Debus D, Meyer C, Papadopoulos T, Schultz ES, Ficker JH, Brueckl WM. Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient. Lung Cancer. 2016;95:35-8.

Brueckl WM, Al-Batran SE, Ficker JH, Wirtz RM, Atmaca A. Estrogen Receptors and their Impact for Prognosis and Therapy of Lung Cancer - New Insights to an Underestimated Mechanism. Pneumologie. 2015;69(6):350-60.

 

Atmaca A, Al-Batran SE, Wirtz RM, Werner D, Zirlik S, Wiest G, Brueckl WM. The validation of estrogen receptor 1 mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancer. Int J Cancer. 2014;134(10):2314-21.

 

Wiewrodt R, Serke M, Grohe C, Brueckl WM. Employing tyrosine kinase inhibitors in the first line treatment of EGFR-positive metastatic NSCLC - state of the art and recent developments. Pneumologie. 2013;67(9):494-501.

 

Brueckl WM, Al-Batran SE, Ficker JH, Claas S, Atmaca A, Hartmann A, et al. Prognostic and predictive value of estrogen receptor 1 expression in completely resected non-small cell lung cancer. Int J Cancer. 2013;133(8):1825-31.

 

Brueckl WM. Should we always use EGFR mutation analysis prior to palliative firstline therapy of metastatic adenocarcinoma of the lung? . Dtsch Med Wochenschr. 2012;137(12):592.

 

Brueckl WM, Wiest GH, Ficker JH. Current status of erlotinib and gefitinib in palliative therapy for NSCLC--does the EGF-R mutation state have any significance?. Pneumologie. 2010;64(12):727-35.

 

Brueckl WM, Schoeberl A, Wirtz RM, Murray S, Hahn EG, Wiest GH. Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC). J Thorac Oncol. 2008;3(3):314-6.

 

Brueckl WM, Lampert S, Zirlik S, Hahn EG, Wiest GH. Drug therapy for small-cell lung cancer (SCLC)--new molecular strategies for therapy. Pneumologie. 2008;62(1):23-30.

 

Patentschriften

Tumormarker zur Diagnose von Karzinomen und / oder davon abstammender Metastasen

PD Dr. W. Brückl, PD Dr. A. Wein, Dr. M. Munnes

Deutsches Patentamt DE 10/2004 037 860.6

Europäisches Patentamt WO 2006 015742

www.wipo.int/pctdb/en/wo.jsp?wo=2006015742

 

• Prediction and prognosis of metastatic CRC by determining serum parameters

Dr. R. Wirtz, M. Averdick, Dr. R. Thiel, PD Dr. A. Wein, PD Dr. W. Brückl

United States Patent and Trademark Office WO 2007 016367

www.wipo.int/pctdb/en/wo.jsp?wo=2007016367

 

Prediction and prognosis of metastatic CRC by expression profiling in fresh and fixed tumor tissue

Dr. R. Wirtz, Dr. M. Munnes, Dr. A. Schuppert, PD Dr. A. Wein, PD Dr. W. Brückl

United States Patent and Trademark Office (eingereicht 2007)

 

Molecular markers to predict response to chemotherapy and EGFR family inhibition by targeted strategies in lung cancer

PD Dr. W. Brückl, Dr. R. Wirtz

United States Patent and Trademark Office 2007 (eingereicht 12/2007)

 

[nach oben]

 

[nach oben]

Publikationen

               

[nach oben]

 
Es öffnet sich eine Seite auf klinikum-nuernberg.de mit Notfallinformationen
Bitte spenden sie


AbstandhalterMarke Stadt Nürnberg

Übersicht

Aktuelles

Unternehmen

Bildung

Partner

Service

Zentren